RxDoctor Payments Data

Timothy Pendleton, MD

Pulmonary Disease · Brookville, PANPI 1801862693

Payments from drug & device makers

$852in general payments, 2019–2025

Across 49 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$206
  • Johnson & Johnson$176
  • Grifols USA, LLC$95
  • Regeneron Healthcare Solutions, Inc.$85
  • Inspire Medical Systems, Inc.$80
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$852 in reported general payments places this provider in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,017
Medicare patients
54
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter236$169,540
XolairOmalizumab42$113,224
Dupixent SyringeDupilumab12$45,730
Breo ElliptaFluticasone/Vilanterol91$42,006
Fluticasone-SalmeterolFluticasone Propion/Salmeterol137$21,917
Incruse ElliptaUmeclidinium Bromide48$20,163
Spiriva RespimatTiotropium Bromide16$12,150
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$11,341
Ventolin HfaAlbuterol Sulfate107$8,427
Advair HfaFluticasone Propion/Salmeterol22$7,361
Albuterol Sulfate HfaAlbuterol Sulfate189$6,984
Arnuity ElliptaFluticasone Furoate16$5,984
XareltoRivaroxaban11$5,540
Tiotropium Bromide17$5,256
Fluticasone Propionate108$4,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$206$249,034417 claims
Johnson & JohnsonXarelto$176$5,54011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Brookville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →